Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R N Fedorak

Showing results (61-70 of 86) with videos related to

Pageof 9
Sort By:
Canadian Journal of Physiology and Pharmacology|April 1, 1991
Fish oil-enriched diet is mucosal protective against acetic acid-induced colitis in ratsL R Empey, L D Jewell, M L Garg, et al.
Alimentary Pharmacology & Therapeutics|September 5, 2014
Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's diseaseC Ma, V Huang, D K Fedorak, et al.
JPEN. Journal of Parenteral and Enteral Nutrition|July 27, 1999
Trace element contamination of total parenteral nutrition. 1. Contribution of component solutionsM M Pluhator-Murton, R N Fedorak, R J Audette, et al.
JPEN. Journal of Parenteral and Enteral Nutrition|July 27, 1999
Trace element contamination of total parenteral nutrition. 2. Effect of storage duration and temperatureM M Pluhator-Murton, R N Fedorak, R J Audette, et al.
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|November 5, 1997
Health economics of gastroesophageal reflux diseaseD Sadowski, M Champion, R Goeree, et al.
Journal of Pediatric Surgery|June 1, 1990
The physiology of adaptation to small bowel resection in the pig: an integrated study of morphological and functional changesD L Sigalet, G M Lees, F Aherne, et al.
Gastroenterology|February 1, 1994
Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study GroupE J Irvine, B Feagan, J Rochon, et al.
Gastroenterology|April 1, 1997
A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study GroupL R Sutherland, F Martin, R J Bailey, et al.
The New England Journal of Medicine|June 30, 1994
Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial InvestigatorsB G Feagan, J W McDonald, J Rochon, et al.
Gastroenterology|December 13, 2000
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study GroupR N Fedorak, A Gangl, C O Elson, et al.
Pageof 9

Showing results (61-70 of 86) with videos related to

Sort By:
Pageof 9
Canadian Journal of Physiology and Pharmacology|April 1, 1991
Fish oil-enriched diet is mucosal protective against acetic acid-induced colitis in ratsL R Empey, L D Jewell, M L Garg, et al.
Alimentary Pharmacology & Therapeutics|September 5, 2014
Adalimumab dose escalation is effective for managing secondary loss of response in Crohn's diseaseC Ma, V Huang, D K Fedorak, et al.
JPEN. Journal of Parenteral and Enteral Nutrition|July 27, 1999
Trace element contamination of total parenteral nutrition. 1. Contribution of component solutionsM M Pluhator-Murton, R N Fedorak, R J Audette, et al.
JPEN. Journal of Parenteral and Enteral Nutrition|July 27, 1999
Trace element contamination of total parenteral nutrition. 2. Effect of storage duration and temperatureM M Pluhator-Murton, R N Fedorak, R J Audette, et al.
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|November 5, 1997
Health economics of gastroesophageal reflux diseaseD Sadowski, M Champion, R Goeree, et al.
Journal of Pediatric Surgery|June 1, 1990
The physiology of adaptation to small bowel resection in the pig: an integrated study of morphological and functional changesD L Sigalet, G M Lees, F Aherne, et al.
Gastroenterology|February 1, 1994
Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study GroupE J Irvine, B Feagan, J Rochon, et al.
Gastroenterology|April 1, 1997
A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study GroupL R Sutherland, F Martin, R J Bailey, et al.
The New England Journal of Medicine|June 30, 1994
Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial InvestigatorsB G Feagan, J W McDonald, J Rochon, et al.
Gastroenterology|December 13, 2000
Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study GroupR N Fedorak, A Gangl, C O Elson, et al.
Pageof 9